Puma Biotechnology | PBYI - Pasivo Circulante





Pasivo Circulante Cambio Fecha
Agios Pharmaceuticals USD 70.22M 11.37M 2026-06
Alnylam Pharmaceuticals USD 1.51B 163.04M 2026-06
Amgen USD 25.5B 547M 2026-06
Biogen USD 3.92B 918.2M 2026-06
BioMarin Pharmaceutical USD 1.66B 870.84M 2026-06
Daiichi Sankyo JPY 765.7B 119.32B 2026-06
Exelixis USD 361.93M 9.05M 2026-06
Gilead Sciences USD 11.02B 1.54B 2026-06
Glaxosmithkline GBP 22.43B 6.39B 2026-03
Incyte USD 1.31B 177.55M 2026-06
MacroGenics USD 108.82M 12.88M 2026-06
Moderna USD 2.53B 139M 2026-06
Novartis USD 31.75B 374M 2026-06
Pfizer USD 32.65B 1.7B 2026-06
PTC Therapeutics USD 771.07M 152.54M 2026-06
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 5.53B 422.9M 2026-06
Roche Holding CHF 28.85B 846M 2026-06
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sarepta Therapeutics USD 502.91M 3.74M 2026-06
Takeda JPY 2.76T 335.02B 2026-06
TG Therapeutics USD 268.49M 81.38M 2026-06
Ultragenyx Pharmaceutical USD 351M 26M 2026-06
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Vertex Pharmaceuticals USD 3.94B 57.3M 2026-06